MTR 0.00% $3.95 metal tiger plc


  1. 2,839 Posts.
    MTR Press Release,

    Meditech says safety trial of anti-cancer drug successful
    MELBOURNE, May 16 AAP - Drug development company Meditech
    Research Ltd will move towards a Phase II trial of anti-cancer drug
    HyDox after the success of the Phase 1 safety trial.
    The company said patients with advanced stages of cancer had
    been safely administered progressively higher doses of HyDox in the
    Phase 1 trial.
    "This allows Meditech to begin planning design of its Phase II
    clinical trial of HyDox," the company said.
    Meditech said results of the Phase I trial were expected to be
    available to shareholders by the end of June.
    Meditech shares were 1.5 cents higher at 36.5 cents at 1314 AEST

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.